Nuveen AMT-Free Municipal Credit Income Fund (NVG) Stock Price

12.60 ▼ -0.08 (-0.63%)
Open: 12.62 Vol: 0 Day's range: 12.59 - 12.62 Apr 29, 11:28 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
NVG Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 12.60▼ 12.60▼ 12.62▼ 12.63▼ 12.61▼
MA10 12.60▼ 12.62▼ 12.62▼ 12.63▼ 12.63▼
MA20 12.62▼ 12.62▼ 12.62▼ 12.61▼ 12.74▼
MA50 12.62▼ 12.61▼ 12.62▼ 12.73▼ 12.36▲
MA100 12.62▼ 12.61▼ 12.64▼ 12.75▼ 12.48▲
MA200 12.61▼ 12.58▲ 12.48▲ 12.46▲ 12.17▲
  5 mins 30 mins Hourly Daily Weekly
MACD -0.002▼ -0.005▼ -0.004▼ 0.012▲ -0.054▼
RSI 36.799▼ 42.979▼ 44.036▼ 48.440▼ 49.293▼
STOCH 44.444     26.667     47.801     48.294     38.022    
WILL %R -100.000▼ -100.000▼ -88.889▼ -75.714▼ -59.821    
CCI -108.676▼ -140.639▼ -131.376▼ -70.316     -35.960    
Latest Filters Detected On NVG
RSI $NVG RSI(14) Crossed Below 50 Set Alert
MA $NVG Price Crossed Below MA(13) Set Alert
MA $NVG Price Crossed Below MA(7) Set Alert
Nuveen AMT-Free Municipal Credit Income Fund News
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
Monday, April 27, 2026 04:44 AM
NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and ...
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
Monday, April 13, 2026 11:46 AM
NervGen Pharma Corp. (“NervGen” or the “Company”) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and ...
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
Tuesday, April 07, 2026 05:23 AM
Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia.Primary endpoint will be the change from baseline in GRASSP ...
NVG historical stock data
date open high low close volume
29/04/26 12.61 12.62 12.585 12.585 150,324
28/04/26 12.62 12.68 12.56 12.68 525,653
27/04/26 12.62 12.67 12.59 12.63 446,930
24/04/26 12.64 12.645 12.55 12.62 483,920
23/04/26 12.63 12.65 12.55 12.64 279,869
22/04/26 12.66 12.67 12.57 12.63 268,189
21/04/26 12.69 12.70 12.575 12.65 440,797
20/04/26 12.67 12.68 12.5701 12.68 466,893
17/04/26 12.63 12.66 12.565 12.64 455,819
16/04/26 12.63 12.63 12.50 12.52 417,676
Quote Details
52wk Low:11.50
52wk High:13.59
Vol:0
Avg Vol(3m):13.1M
1Y Chng:+4.70%
1M Chng:-0.75%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 2.89B